PPARG and type 2 diabetes mellitus: Treatment with rosiglitazone resulted in a significant stimulation of SCD expression (Table 2) which is consistent with an increase in SCD expression in muscle samples reported by Tonelli et al. for pioglitazone (a different PPARγ agonist) treatment of subjects with type 2 diabetes [40].